Document is current
Any future updates will be listed below
-
Authors
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Taylor, Peter C.
Ritsema, Jeffrey A. S.
Kondo, Akira
Kaise, Toshihiko
-
Funding
Funding for this research was provided by:
Gilead Sciences
- License Information
-
More Information
Article History
Received: 17 December 2025
Accepted: 2 February 2026
First Online: 28 March 2026
Declarations
:
: Yoshiya Tanaka has received speaking fees and/or honoraria from Chugai, UCB, Abbvie, AstraZeneca, Eli Lilly & Co, Behringer-Ingelheim, GlaxoSmithKline, Eisai, IQVIA, Daiichi-Sankyo, Otsuka, Taisho, Gilead, Bristol-Mayers. Yoshiya Tanaka is an Editorial Board member of Rheumatology and Therapy . Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Peter C Taylor has received research grants from Alfasigma, consulting fees from AbbVie, Aceleryn, Alfasigma, Gilead, Takeda, Janssen, Eli Lilly & Co., Nordic Pharma, Roche, and UCB, and has served on safety monitoring boards for Immunovant, Moonlake and Sanofi. Jeffrey A S Ritsema is an employee of Alfasigma Nederland BV. Toshihiko Kaise is an employee of Gilead Sciences K.K. and shareholder of Gilead Sciences, Inc. Akira Kondo is an employee of Gilead Sciences K.K. and may hold shares in Gilead Sciences, Inc.
: As this review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, ethical approval is not required.
